Tetrahydrocannabiphorol

Tetrahydrocannabiphorol
Clinical data
Pronunciation	/tɛtʃrəhaɪdroʊkənæbɪfoʊrɔːl/
Other names	(-)-Trans-Δ9-tetrahydrocannabiphorol,; Δ9-THCP,; (C7)-Δ9-THC,; THC-Heptyl
Drug class	Cannabinoid
Identifiers
	IUPAC name (6aR,10aR)-3-heptyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;
CAS Number	54763-99-4;
PubChem CID	6453074;
ChemSpider	4955468;
UNII	WTK87HN3LG;
CompTox Dashboard (EPA)	DTXSID70203228 ;
Chemical and physical data
Formula	C23H34O2
Molar mass	342.523 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCc3cc2OC(C)(C)[C@@H]1CCC(C)=C[C@H]1c2c(O)c3;
	InChI InChI=1S/C23H34O2/c1-5-6-7-8-9-10-17-14-20(24)22-18-13-16(2)11-12-19(18)23(3,4)25-21(22)15-17/h13-15,18-19,24H,5-12H2,1-4H3/t18-,19-/m1/s1; Key:OJTMRZHYTZMJKX-RTBURBONSA-N;

Tetrahydrocannabiphorol (THCP) is a potent phytocannabinoid, a CB₁ and CB₂ receptor agonist which was known as a synthetic homologue of tetrahydrocannabinol (THC), but for the first time in 2019 was isolated as a natural product in trace amounts from Cannabis sativa.

THCP is structurally similar to Δ⁹-THC, the main active component of cannabis, but with the pentyl side chain extended to heptyl. Since it has a longer side chain, its cannabinoid effects are "far higher than Δ⁹-THC itself." Tetrahydrocannabiphorol has a reported binding affinity of 1.2 nM at CB₁, approximately 33 times that of Δ⁹-THC (40 nM at CB₁), however this does not mean it's 33x stronger per milligram.

THCP was studied by Roger Adams as early as 1942.